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Abstract
Over 400 distinct canine breeds today were result from artificial selection
during the last centuries. And due to the selection pressure from human
interest and the founder effects, the difference among individual genomes
from one same breed is less than the difference between breeds. 446 samples
were included in this study to recognize the cancer-associated nonsense
mutations in canine genome. 17 of the 446 samples were lab-recruited dogs,
and the other 429 samples were downloaded from Sequence Read Archive.
One nonsense mutation in GSDMC protein is found significantly associated
with cancer risk in dogs. Since nonsense mutations could provide premature
proteins or shortened mRNA lifespan, given that the potential function of
GSDMC in cell death pathways, our study results provide clues for
pathological function of GSDMC in cancer.
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Introduction
The overall aim of this study is to recognize disease-associated gene
mutations among the next-generation sequencing (NGS) data from canine
models. Specifically, this study aims to find homozygous nonsense mutations
in dogs related to higher cancer risk, including the hypothesis generation and
validation steps.
Canine is an excellent model for human cancer genetic research. Though the
domestication of dog took place at around 10,000 years BP, but over 400
distinct breeds today were result from artificial selection during the last
centuries. 1 As a result of deliberate breeding over the hundreds of years,
many canine breeds have been established. Due to the selection pressure from
human interest and the founder effects, the difference among individual
genomes from one same breed is less than the difference between breeds.2 In
addition to the isolated breeding population structure, dog, as a large animal,
is more similar to human in the degree of life span and physiology comparing
to mouse.3 Spontaneous neoplasia was observed in dogs like in human and
many genes related with canine cancer are orthologs of human, according to
Online Mendelian Inheritance in Animals (OMIA).4 Comparing with mouse
genome, canine genome has less differences with human genome, thus
providing a more precise model.5 Besides, dogs share similar environment
with owners, which allows them serve as animal model for further gene
environment interaction research.
This study focused on the nonsense mutations to enhance the significance.
The nonsense mutations, also known as stop-gained mutations, refer to point
mutations resulting in an early presented stop codon in the transcribed mRNA
sequences, which could finally provide premature proteins. Nonsense
mutations could also cause shortened mRNA lifespan through activating
nonsense-mediated mRNA decay (NMD), which leads to difficulty in
producing truncated proteins. 6 The nonsense mutation is one of the most
severe mutation types and generate loss of function mutation, and nonsense
mutations were proved to be related with multiple chronic diseases in human,
such as Cystic fibrosis7, Beta thalassaemia8, and multiple cancers.9
The breed-specific homozygous nonsense mutations are investigated. If one
homozygous nonsense mutation takes a much larger fraction of the population
in breeds with high risks of cancer compared to the breeds with lower risks,
the mutation is probably responsible for cancer development. Based on this
logic, homozygous stop-gained mutations which have the largest fraction
difference between the two groups could provide valuable cues for hypothesis
development.

Background
Previous population studies showed that cancer was the most common canine
causes of death, around four million dogs were affected per year.10,11 In the
cohort study by J.M. Fleming et al., 74,556 dogs in North America were
followed for the research of breed-related causes of death. And the death
causes of 15,881 samples were collected by V. J. ADAMS et al., in a health
survey of purebred dogs in the UK. Both studies reported proportion of cancer
caused death to vary among different breeds. Generally, dogs from breeds
with smaller adult body mass live longer than dogs from breeds with larger
adult body mass, and dogs from smaller also have lower risk of death from
cancer.12,13
Several forms of naturally occurring tumors and cancer have been found to
exist in both human and dogs, and dogs provide a powerful model for
improving the understanding of cancer biology as well as developing cancer
treatments. As reviewed by Pinho, S. S., et al., canine mammary tumors could
serve as valuable tools for studying human breast cancer.14 The human and
canine osteosarcoma are similar, while the incidence in dogs are
approximately 10 times to that in people, which addressed the use of canine
osteosarcoma to study human osteosarcoma.15,16
Genes associated with canine caner also could help the cancer research in
people. HYAL1, HYAL2, HYAL3, HYAL4, SPAM1 and HYALP1 has been
found to be associated with mast cell tumors in golden retrievers, and the
variant genes and genetic networks are important in both dogs and human.17
A GWAS study for canine osteosarcoma study has identified prominent
cancer genes CDKN2A/B, AKT2, and BCL2. 18 In standard poodles,
mutations in coat color control genes KITLG and MC1R are related with
squamous cell carcinoma.19

Research Design
Whole genome sequencing
446 samples were included in this study. 17 of them were lab-recruited dogs
from 12 breeds. WGS data of the other 429 samples were downloaded from
Sequence Read Archive. Afterwards, the raw sequencing data was cleaned
and aligned to the reference genome (ROS_Cfam_1.0), annotation software
was used to find all potential single-nucleotide mutations. The cleaning and
alignment process was done by Zicheng following standard guidelines. BWA
package was used for mapping sequences to a reference genome and GATK

was used for realignment and annotation. To focus on sequencing alleles, in
this study calling of genotypes was skipped and sites with major allele
frequency smaller than 0.9 was not included. Genotypes will be studied in
further studies. In addition, to ensure the alleles data solid and compelling,
sites with combined allele depth no larger than 10 was not included in this
study.
Hypothesis generation
The 17 lab-recruited samples were used for hypothesis generation. The 17
dogs were classified into two groups based on their breed-level cancerspecific mortality rate data from the cohort study by J.M. Fleming et al. and
the cohort study by V. J. ADAMS et al. Because according to previous study,
nearly 30% of dogs die from cancer in average, samples with breed-level
cancer-specific mortality rate higher than 30% were labeled as “High cancer
risk”, while the samples with mortality rate lower than or equal to 30% was
labeled as “Low cancer risk”. Programs are made to count the number of each
homozygote nonsense mutations carriers for the two groups separately. Then
the counts are divided by the group size to estimate the prevalence of
mutations. After that, the difference of the prevalence is calculated by
prevalence in the higher-risk group minus prevalence in the lower-risk group.
All identified premature mutations were ranked based on the difference of
prevalence of mutation between the two groups. Top 5 ranked stop-gained
mutations were used for the following validation process.
Validation of the association between the cancer risk and mutations
The 429 samples downloaded from Sequence Read Archive were used for
validation. 645 samples were available from Sequence Read Archive, but
some samples were excluded because they have no breed-level ratio of death
from cancer, in which case we can’t evaluate the cancer risk of the sample.
Fisher’s exact test was used and the null hypothesis is that ratio of cancer
death in two groups are not different. To address the multiple comparisons
fallacy, Bonferroni correction is applied. Because five sites were tested, the
alpha-value needs to shrink from 0.05 to 0.01.

Result
Watson, Colby, Anna, Louis, RB, and 6LR are the 6 samples with a higher
risk of cancer, while the other 11 samples are in the lower risk group. (Table
1) The top five candidate stop-gain mutation sites with the largest mutation
prevalence difference between the high cancer risk group and the low cancer
risk group were identified from our discovery dataset. (Table 2) It can be

hypothesized that these five mutations are related to a higher risk of cancer in
dogs, and the association between cancer risk and each of the four mutations
is evaluated in the next step.
Table 1 Ratio of death caused by cancer

Group

High
cancer
risk

Low
cancer
risk

Breed

Ratio of death
caused by
cancer*

Sample ID**

GOLDEN RETRIEVER

0.4782

Watson, Colby

FRENCH BULLDOG

0.3803

LABRADOR RETRIEVER

0.3367

Anna, Louis,
RB
6LR

CHESAPEAKE BAY
RETRIEVER

0.2849

Graham

GERMAN SHEPHERD DOG
AMERICAN ESKIMO DOG

0.2770
0.2376

GS, Scotia
4AE

AUSTRALIAN SHEPHERD

0.2365

5AS

ENGLISH BULLDOG
DACHSHUND

0.1992
0.0891

1Y, 2O
3D

PEKINGESE
CHIHUAHUA
MINIATURE PINSCHER

0.0795
0.0750
0.0357

DW
2C
1MP

Note:
* Published breed-level data from the study by J.M. Fleming et al. and the study by V. J. ADAMS et al.
**Samples firstly sequenced in this study

Table 2 Mutation with top prevalence difference

Rank
1
2
3
4
5

Prevalence Difference
0.7142
0.6667
0.6667
0.6071
0.6000

Chr
13
13
18
36
12

Position
27257932
59889202
54475267
4708056
2378563

Gene
GSDMC
LOC119874465
LGALS12
DAPL1
LOC102156885

Mutation
G>T
C>A
G>A
C>T
C>T

429 samples were collected from online resources. Then samples with depth
no larger than 10 or potentially heterozygous were remover. And the samples
passed the filter were divided into two groups based on their breed-level risk
of cancer – samples belonging to breed with a ratio of death from cancer lower
than 0.30 were categorized in the low-risk group, while those with a ratio
equal or larger than 0.30 were categorized in the high-risk group.
Fisher exact test (Table 3) was then employed to validate the effect of the
mutations on cancer risk. For mutation in gene GSDMC, the null hypothesis
is that cancer risk is the same samples with or without the homozygous
nonsense mutation. With the two-tailed p-value smaller than 0.01 (p = 0.0008),

the null hypothesis is rejected and the homozygous nonsense mutation in
GSDMC is significantly associated with cancer risk. The other four mutations
were tested as well. (Table 3) With the p-values greater than 0.01, null
hypotheses failed to be rejected. Therefore, none of them are significantly
associated with higher cancer risk.
Table 3 Validation of the mutations

Number of
samples
Alt
Ref

Gene
GSDMC
High risk
Low risk

69
41

p-value†
0.0008*

67
94

LOC119874465

0.1485
High risk
Low risk

18
20

98
189

LGALS12

0.3643
High risk
Low risk

26
31

88
143

DAPL1

0.0658
High risk
Low risk

29
35

55
120

LOC102156885

0.6311
High risk
Low risk

17
33

83
136

Note:
† P-value calculated from the Fisher exact test
* Statically significant

Discussion
Position of the nonsense mutation in GSDMC
GSDMC is a gene in canine Chromosome 13 and the nonsense mutation
NC_051817.1:g.27257932G>T is located in the fourth exon of GSDMC (Fig
1). The mutation locates in the 601st base out of 1524 nucleotides in the
protein-coding region. Because there were no existing mRNA expression data
based on the reference genome ROS_Cfam_1.0, the mutation was located in
an older form of reference genome CanFam3.1 to study its effect on mRNA
and protein expression. And the mutation causes the protein premature at the
201st residue out of 507 residues (Fig 2).

Based on the Ensembl database, only one transcript was reported. Till now,
no alternative splicing of this gene has been reported. This stop gain mutation
would cause 40 residues lost in the C-terminus of the pore forming domain
and loss of the whole PUB domain (Fig 2).

Reference DNA sequence
DNA

sequence

mutation

Fig 1. Position of the nonsense mutation in GSDMC DNA sequence
Note: Based on a screenshot from gene viewer, NCBI

Fig 2. Position of the nonsense mutation in GSDMC transcript
Note: Based on a screenshot from Ensembl, red arrows indicate the mutation position

The potential function of GSDMC
GSDMC gene expresses Gasdermin C, a protein belonging to the Gasdermin
family. The gasdermin-N domains of human GSDMC were proved to induce
extensive pyroptosis in human 293T cells, while the full-length GSDMC
protein shows little cytotoxicity.20 In a recent study, the caspase-8-mediated
cleavage of GSDMC induced pyroptosis, reducing the repression of tumor
growth. 21 Though cleavage of GSDMC was proved by several studies to
suppress tumorigenesis, the effect of GSDMC expression is controversial:
high-level expression of GSDMC was reported in colorectal and lung cancers,
while in gastric and esophageal cancer expression of GSDMC were reported
to suppress tumor progression. 22 , 23 , 24 In addition, the function of the C

with

nonsense

terminal domain in GSDMC has not been studied before. In this study, we
find nonsense mutation NC_051817.1:g.27257932G>T in GSDMC is
associated with a higher risk of cancer in canines, which suggests that dogs
could serve as good animals models for GSDMC function research in the
future.
Strength of the study
This study first reported the association between the identified GSDMC stopgain mutation and increased chances to die from cancer in dogs, providing
supports for that the normal GSDMC function is essential for preventing
tumor development. This study also hints that, dogs could serve as great
model for the in vivo function study on GSDMC.
The study was based on high-depth whole genome sequencing data, ensuring
the sequencing accuracy. In addition, the filter based on the sequencing depth
and allele proportion of alleles helped recognize true mutations. Tradition
studies started with disease-associated haplotype blocks and then search for
biologically meaningful mutations. Different from the tradition studies, this
study focused on the stop-gain mutations directly, enhancing the biological
significance.
Limitation of the study
This study didn’t consider the linkage disequilibrium. Because many dog
breeds were developed from a few dogs, the founder event leads to genetic
diversity within breeds. Previous study has also proved the high levels of
linkage disequilibrium in dogs. 25 This study didn’t investigate mutations
other than stop-gain mutation. Mutations associated with the nonsense
mutation could cause the higher cancer risk. As a result, linkage group could
be studied in the future to decide if other mutations nearby have correlation
with the mutation in GSDMC could lead to increased ratio of death from
cancer.
As discussed previously, dogs from breeds with larger body weight are more
frequent to die from cancer compared with dogs with dogs with lighter body
weight, while dogs from breeds with longer lifespan were more easily to die
from tumor.26,27 The nonsense mutation could be related with body size or
average age of the breeds. Relationship between breed body weight and the
mutation, as well as the relationship between breed average age and the
mutation were not analyzed in this study. And average age and body size
should be controlled in further investigation.
The cancer risk was estimated by the ratio of death caused by neoplasm to allcause death. And the ratio was breed-level data summarized from previous
studies, but not based on the actual individual cause of death, which could

weaken the accuracy of the study. When analyzing the whole genome
sequencing data, sample size of some breeds was small, causing many
extreme values in the breed-level alternative allele prevalence in the
validation step. Such extreme values could reduce the precision of the study.

Conclusion
Based on high-depth whole genome sequencing data, this study found the
association between a nonsense mutation in GSDMC and increased chances
to die from cancer in dogs, providing supports for that the normal GSDMC
function is essential for preventing progression of cancer. As discussed
previously, this study lacked the investigation on potential linkage
disequilibrium, confounders, and individual-level cancer risk data. In addition
to the limitation, further research could also focus on the pathological function
of GSDMC using dogs as animal models to study human cancer.
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